ST葫芦娃(605199.SH)获得头孢地尼胶囊药品注册证书

Core Viewpoint - ST HuLuWa (605199.SH) has received the drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Company Summary - The newly approved Cefdinir is a third-generation broad-spectrum cephalosporin antibiotic, effective against various bacterial strains including Staphylococcus, Streptococcus, and Escherichia coli [1] - The drug is indicated for treating multiple infections such as pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, and urinary tract infections among others [1] - The approval was granted based on the drug meeting the technical requirements for quality and efficacy consistent with reference formulations, which also implies passing the consistency evaluation for generic drugs [1] Industry Summary - The approval of Cefdinir capsules reflects the ongoing regulatory support for antibiotic development in the pharmaceutical industry, particularly for broad-spectrum antibiotics [1] - The market for antibiotics is critical, given the rising concerns over antibiotic resistance and the need for effective treatments for bacterial infections [1]